171 related articles for article (PubMed ID: 34904684)
1. Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis.
Mälkönen T; Nuutinen P; Hallinen T; Soini E; Nissinen R; Wennerstöm C; Rantanen T; Hagman JH; Harvima R; Höök-Nikanne J; Ilves T; Lintu P; Malanin K; Soramäki I; Tasanen K; Teho A; Vähävihu K; Itälinna S; Leinonen P; Sarajärvi P; Huilaja L; Pasternack R
Acta Derm Venereol; 2022 Jan; 102():adv00631. PubMed ID: 34904684
[TBL] [Abstract][Full Text] [Related]
2. Real-life experience of guselkumab in patients with psoriasis.
Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
[TBL] [Abstract][Full Text] [Related]
3. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
[TBL] [Abstract][Full Text] [Related]
5. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
[TBL] [Abstract][Full Text] [Related]
6. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care.
Seidl U; Pinter A; Wilsmann-Theis D; Poortinga S; Morrison K; Mrowietz U; Gerdes S
Dermatol Ther; 2022 Jan; 35(1):e15193. PubMed ID: 34741783
[TBL] [Abstract][Full Text] [Related]
7. Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis.
Marletta D; Murgia G; Cattaneo A; Carrera C; Marzano A
J Drugs Dermatol; 2022 Aug; 21(8):864-866. PubMed ID: 35946964
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
[TBL] [Abstract][Full Text] [Related]
10. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Ruggiero A; Fabbrocini G; Cinelli E; Megna M
Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
[TBL] [Abstract][Full Text] [Related]
11. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
[TBL] [Abstract][Full Text] [Related]
12. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.
Bardazzi F; Viviani F; Merli Y; Di Lernia V; Peccerillo F; Conti A; Lasagni C; Tabanelli M; D'Adamio S; Di Nuzzo S; Cortellazzi C; Filippi F
Expert Opin Biol Ther; 2022 Dec; 22(12):1561-1566. PubMed ID: 35388713
[TBL] [Abstract][Full Text] [Related]
13. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population.
Zhuang JY; Li JS; Zhong YQ; Zhang FF; Li XZ; Su H; Zhang ZQ; Wang XH; Chen YF
Dermatol Ther; 2021 Sep; 34(5):e15054. PubMed ID: 34228392
[TBL] [Abstract][Full Text] [Related]
17. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.
Puig L; Daudén E; Cuervas-Mons M; Novella C; Guisado C
J Eur Acad Dermatol Venereol; 2023 Aug; ():. PubMed ID: 37567861
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
20. The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
Adv Ther; 2023 May; 40(5):2493-2508. PubMed ID: 36930429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
